Educational content on VJDementia is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

AAIC 2023 | The need for revised outcome measures in DLB trials

Carla Abdelnour, PhD, Stanford University, Palo Alto, CA, talks on the lack of sufficient outcome measures to determine a drug’s efficacy, following a systematic review of randomized clinical trials in patients with dementia with Lewy bodies (DLB). The existing outcome measures include scores on the mini-mental state examination (MMSE), the cognitive dementia rating (CDR) and the modified body and soul-unified Parkinson’s disease rating scale (MBS-UBDRS). These are commonly used measures in Alzheimer’s and Parkinson’s disease clinical trials but may not be sensitive enough to detect changes in patients with DLB. Therefore, there is a need for DLB-specific outcome measures which are sensitive enough to detect changes to aid drug development. This interview took place at the Alzheimer’s Association International Conference (AAIC) 2023 in Amsterdam, Netherlands.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.


Carla Abdelnour has received the Sue Berghoff LBD Research Fellowship, and honoraria as speaker from F. Hoffmann-La Roche Ltd, Zambon, Nutricia, Schwabe Farma Ibérica S.A.U. She is member of the Board of Directors of the Lewy Body Dementia Association.